SWOG clinical trial number
S1918
A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIIb Follicular Lymphoma, transformed lymphoma, and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements
Open
Phase
II-III
Accrual
1%
Abbreviated Title
Ph II/III study of R-miniCHOP +/- oral aza in elderly with newly diganosed DLBCL
Status Notes
Activation - Effective 3/19/21, 12:00 pm Pacific Time
Training for Conduct of FIL Tool, accessible from: https://www.swog.org/required-s1918-training.
Online FIL Tool, accessible from: https://redcap.filinf.it/surveys/?s=RF4FPKH799.
Note: Responses must also be submitted in iMedidata RAVE, as indicated in protocol Section 14.5a, along with the score generated by the online FIL Tool.
Training for Conduct of FIL Tool, accessible from: https://www.swog.org/required-s1918-training.
Online FIL Tool, accessible from: https://redcap.filinf.it/surveys/?s=RF4FPKH799.
Note: Responses must also be submitted in iMedidata RAVE, as indicated in protocol Section 14.5a, along with the score generated by the online FIL Tool.
Activated
03/19/2021
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE
Research committees
Lymphoma
Treatment
Cyclophosphamide
Prednisone
Vincristine
Doxorubicin
Filgrastim
Rituximab
Pegfilgrastim
CC-486
CHOP
Other Study Materials
Eligibility Criteria Expand/Collapse
* See S1918 protocol Section 5.0; accessible from the CTSU protocol abstract page at www.ctsu.org.
Other Clinical Trials
SWOG Clinical Trial Number
CTSU/ANHL1931
A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma.
Research Committee(s)
Lymphoma
Activated
06/07/2021
Open
Phase
SWOG Clinical Trial Number
S1918
A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIIb Follicular Lymphoma, transformed lymphoma, and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements
Research Committee(s)
Lymphoma
Activated
03/19/2021
Accrual
1%
Open
Phase
II-III
SWOG Clinical Trial Number
CTSU/EA4181
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients <= 70 Years Old with Untreated Mantle Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
10/03/2019
Open
Phase
II